Article
Mutation of lysine-specific demethylase 5 is associated with enhanced tumor immunity and favorable outcomes in pan-cancer immune checkpoint blockade.
Molecular cancer - 27 Dec 2024
Li Xiaofeng, Zhang Zhishan, Li Yingying, Chen Lijin, Huang Yan, Su Lijuan, Xu Wenjun, Hong Yanni, Li Jianjiao, Chen Mujin, Yang Hongkui, Zhao Hong, Zhao Bin
Abstract excerpt
The lysine-specific demethylase 5 (KDM5) family, a key post-translational modification of chromatin, can shape tumor immune microenvironment. Here, we performed an extensive clinical and bioinformatic analysis to explore the association between KDM5 mutation and tumor immunity and its impact on the outcomes in pan-cancer immunotherapy. In 2943 patients across 12 tumor types treated with immune checkpoint...
Topics
Join the communities discussing this publication.